Liraglutide
Proven for weight, diabetes and heart risk; less loss than weekly drugs.
The older medicine, injected once a day. Weight loss is smaller than on the weekly drugs, but it is off patent and sold as generics. A made by Novo Nordisk and generic makers, also called Victoza and Saxenda.
What the evidence shows
Side effects and risks
Who should avoid it: Pregnancy, medullary thyroid cancer or MEN 2 in you or your family.
How it works
- Where it acts
- GLP-1 receptors in the pancreas, stomach and brain. One injection lasts about a day.
- What it changes
- More insulin when blood sugar is high, a slower stomach and fewer hunger signals.
- What people notice
- Less hunger and moderate weight loss. Nausea is common at the start.
How it is taken
Daily injection under the skin. For weight loss it starts at 0.6 mg and rises weekly to 3 mg. A prescriber sets the schedule.
Getting it in the United States
The legal route for Liraglutide
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Prescription generic from pharmacy
A generic of Saxenda launched in 2025-08 for adults and adolescents aged 12 to 17. The brand list price was about 1,349 dollars a month. The source gives no generic price, so savings depend on insurer and pharmacy.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Telehealth low-dose programmes
At least one large weight-loss app offers liraglutide pens inside a microdosing programme open to people with lower BMI. Doctors quoted by Today call such programmes unproven and experimental.
Source: Today.com, 2025-11
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- A long track record
Reported problems
- A needle every day
- More modest results
- Nausea early on
More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
US poison centre calls on GLP-1 drugs
Harm reportedpoison centre data - 22966 people - 2025
US poison centres logged 22,966 GLP-1 agonist exposure cases from 2019 to 2025, a rise of nearly 1,500 percent in calls. Most were accidental dosing errors. With compounded products, some callers had taken ten times the intended amount after misreading syringe units.
Source: America's Poison Centers, 2025
UK hospitalisations after fake weight-loss pens
Harm reportednews-reported case - 2023
The UK regulator reported that a very small number of people were hospitalised after using potentially fake semaglutide or liraglutide pens bought without a prescription. Effects included hypoglycaemic shock and coma, suggesting the pens held insulin. It had seized 369 suspect pens since January 2023.
Source: MHRA, 2023
What experts and influencers say
Paraphrased from the linked sources.
Launching the first WHO guideline on GLP-1 drugs for obesity, said medicines alone will not solve the crisis but can help millions. The recommendation is conditional because long-term data are limited and costs are high.
Tedros Adhanom GhebreyesusWikipediaRecommends
Photo source: Lula Oficial / CC BY-SA 2.0
Reported that liraglutide cut opioid craving by about 30 percent in a small residential-treatment trial, and called any craving-free time hopeful for patients. Wants larger trials and tests of newer GLP-1 drugs.
Source: Science News, 2024-02
Patricia GrigsonWebsiteRecommends
Photo source: rdar.unl.edu
Announced the US launch of the first generic GLP-1 approved specifically for weight loss, a generic of Saxenda for adults and for adolescents aged 12 to 17.
Ernie RichardsenWebsiteRecommends
Money: Executive at the company selling the generic
Photo source: accessiblemeds.org
Defended the ASA crackdown on online pharmacies advertising weight-loss injections. Argued that powerful prescription-only medicines are among the most harmful things to promote to the public.
Nicky MorganWebsiteWarns against
On the trial in children aged 6 to 11: said weight effects were smaller than in adults, noted more side effects including severe vomiting, and said longer follow-up on growth is needed.
Source: Science Media Centre, 2024-09
Nerys AstburySourceMixed view
Described the child trial as small but well run and the results as positive, while noting liraglutide is weaker than newer adult weight-loss drugs.
Source: Science Media Centre, 2024-09
Stephen O'RahillyWikipediaRecommends
Money: Consults for several drug companies, none for the liraglutide maker since 2017
Ruled against nine advertisers and said every injectable weight-loss treatment is prescription-only. Indirect hints, such as the phrase weight loss injections or pen images, also break the ban on advertising to the public.
Source: Pharmacy Magazine, Jul 2025
Advertising Standards AuthoritySourceWarns against
Called the child trial results positive but said suppressing appetite in growing children could affect growth, and asked for longer studies.
Source: Science Media Centre, 2024-09
Simon CorkWebsiteMixed view
Photo source: aru.ac.uk
Co-authored a study estimating that at least four in ten Australian adults meet criteria for an approved weight-management medicine. Hundreds of thousands more qualify for GLP-1 treatment to prevent repeat heart disease.
Jasmin CastrillonSourceRecommends
Said the pharmacy regulator works with the ASA and MHRA on rule-breaking adverts and will review rulings against six registered pharmacies. Action can target owners, superintendents and individual professionals.
Source: The Pharmacist, Jul 2025
Dionne SpenceSourceWarns against
Brought in tighter rules for online supply. Said medicines should follow a proper consultation and that the regulator had seen too many unsafe online supplies.
Source: ITV News, Feb 2025
Duncan RudkinWebsiteMixed view
Photo source: pharmacyregulation.org
Said the Lasker Award shows industry science can be recognised and that young scientists can do high-impact work inside a company. Credited the many Novo Nordisk researchers behind the drugs.
Source: STAT, 2024-09
Lotte Bjerre KnudsenWebsiteRecommends
Money: Novo Nordisk employee
Photo source: nature.com
Told BBC Breakfast the drugs are meant for people with obesity, yet many treat them as a lifestyle product. Listed nausea, stomach upset and gallstones as side effects.
Source: Eastern Eye, Jan 2025
Ashley CohenWebsiteWarns against
Photo source: pharmacy.biz
Said the injections can work well inside a managed programme. Warned that rules let some patients get them inappropriately and that sales targets must not shape clinical decisions.
Source: Irish News (PA), Jan 2025
Money: Represents community pharmacies that sell these medicines
Warned that GLP-1 drugs offered on social media and websites are often counterfeit. Stated that online sale of these prescription drugs is banned in France and that agencies never put their logo on products.
Source: ANSM, Sep 2025
Welcomed approved generic semaglutide at about 100 dollars a month. Said compounded versions carry more risk because nobody reviews them. Unsure whether generics will displace the grey market.
Source: Science-Based Medicine, 2026-09
Scott GavuraSourceMixed view
Warned of a sharp rise in illegal products sold as GLP-1 drugs. Authorities found hundreds of fake Facebook profiles, adverts and listings, many hosted outside the EU and misusing official logos.
Source: EMA, Sep 2025
EMA and Heads of Medicines AgenciesSourceWarns against
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Teva Launches First Generic GLP-1 Drug for Obesity
Covers the launch of the first generic Saxenda (liraglutide) for weight loss in adults and teens, with notes on brand list price and patient costs.
Short news brief on the first generic GLP-1 for weight loss.
When options run out
Uses people turn to when standard treatment has failed.
Opioid craving in residential treatment
- Who
- People with opioid use disorder whose cravings persist despite standard care.
- Evidence
- One 20-person, 19-day placebo-controlled pilot showed about 30 percent less craving. Several dropped out at higher strengths, mostly from nausea and other gut symptoms. Needs confirmation.
Source: Science News, 2024-02
Obesity in children under 12
- Who
- Families of children aged 6 to 11 with common obesity, an age group with no approved medicine for it.
- Evidence
- One 56-week phase 3 trial: about 46 percent on liraglutide cut BMI by 5 percent or more, versus 9 percent on placebo, with more gut side effects. Independent experts want longer growth and puberty data.
Source: Science Media Centre, 2024-09
Idiopathic intracranial hypertension
- Who
- People with this rare raised-brain-pressure condition trying to avoid shunt or stent surgery.
- Evidence
- Liraglutide was one of six GLP-1 drugs pooled in a 1,110-patient US records study showing fewer symptoms and procedures. No drug-specific result. Retrospective only.
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Position 20 carries a palmitic-acid side chain.
Questions people ask
What is the difference between Saxenda and Victoza?
Both are liraglutide. Victoza is the type 2 diabetes brand, and Saxenda is used for weight management.
How does liraglutide compare with the weekly GLP-1 drugs?
Liraglutide is injected daily and causes less weight loss than the weekly drugs. In the SCALE trial, average loss was about 8% at 56 weeks, against 2.6% on placebo.
Is generic liraglutide available?
Yes. It is off patent, and generic liraglutide is sold in the US and in some EU countries.
What are the side effects of liraglutide?
Nausea, diarrhea, constipation and vomiting are common, with nausea most likely at the start. Serious risks include pancreatitis, gallbladder disease and a boxed warning for thyroid C-cell tumors seen in rodents.
Does liraglutide lower heart risk?
In the LEADER trial, major cardiac events fell 13% in people with type 2 diabetes at high risk.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem